Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Start-ups
Trio of Texas biotech firms win total of $50 million in grants for cancer
by Ryan Cross
August 31, 2018
| A version of this story appeared in
Volume 96, Issue 35
The Cancer Prevention & Research Institute of Texas is supporting 16 Texas institutions with more than $177 million. Three grants, totaling more than $50 million, are heading to a trio of biotech firms. Forbius will receive nearly $19 million to evaluate an anti-EGFR antibody-drug conjugate in Phase IIa clinical trials. Korysso Therapeutics will receive nearly $20 million to develop compounds that treat neurological damage caused by cancer chemotherapy. And CerRx will receive nearly $12 million to test combination drug therapies in lymphoma.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X